NA
BNTC icon

NewEdge Advisors’s Benitec Biopharma BNTC Stock Holding History

NewEdge Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-671
Closed -$8.48K – 3979
2024
Q4 		$8.48K Buy
671
+61
+10% +$659 ﹤0.01% 3080
2024
Q3 		$5.61K Buy
+610
New +$5.46K ﹤0.01% 3135

Other funds holding BNTC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NewEdge Advisors's BNTC Position: Q1 2025 in Review

NewEdge Advisors sold out of Benitec Biopharma (BNTC) in Q1 2025, closing a stake of 671 shares — an estimated $8.48K sold.

NewEdge Advisors first reported a position in BNTC in Q3 2024 and held it in 2 quarters. The position peaked at $8.48K in Q4 2024. 37 funds tracked by Wall St. Rank hold BNTC as of Q1 2025.

  • NewEdge Advisors reported no remaining Benitec Biopharma position as of Q1 2025 after selling out during the quarter.
  • NewEdge Advisors sold 671 Benitec Biopharma shares in Q1 2025, an estimated $8.48K.
  • NewEdge Advisors first reported a position in Benitec Biopharma in Q3 2024 and held it in 2 quarters.
  • NewEdge Advisors's Benitec Biopharma position peaked at $8.48K in Q4 2024.
  • 37 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2025.

Based on NewEdge Advisors's 13F filing for Q1 2025, filed 15 May 2025.